文献速递白血病

数字PCR检测慢性髓细胞白血病患者国际标准化BCR::ABL1(P210)mRNA的室间比对

[Inter-laboratory comparison of international standardized BCR::ABL1 (P210) mRNA of chronic myeloid leukemia patients by digital PCR].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

该多中心比对实验研究通过室间样本派发,评估数字PCR(dPCR)检测慢性髓细胞白血病患者BCR::ABL1(IS)的能力。37种不同水平样本中,14家实验室参与dPCR比对,13家所有样本均可检出;采用合格转换系数(CF)时,dPCR与RQ-PCR结果差异无统计学意义(均P≥0.1)。结论认为dPCR检测BCR::ABL1(IS)具有高敏感性、高准确性及与RQ-PCR结果的高度一致性。

要点

  • dPCR检测BCR::ABL1(IS)敏感性高、准确性好,与RQ-PCR结果高度一致。
  • 采用合格CF时,各实验室dPCR与RQ-PCR的BCR::ABL1(IS)结果差异无统计学意义(均P≥0.1)。
  • RQ-PCR原CF不合格的6家实验室中,2家dPCR与原CF的RQ-PCR结果差异有统计学意义(均P<0.05)。

核心结论

  • dPCR检测BCR::ABL1(IS)具有高敏感性、高准确性以及与RQ-PCR结果的高度一致性。

研究设计与样本

  • 本研究为多中心比对实验研究,统一制备37种不同BCR::ABL1(IS)水平的待废弃临床样本用于比对。
  • 22种样本用于RQ-PCR检测以再验证转换系数(CF),其余15种加上用于RQ-PCR的6种用于dPCR比对。
  • 北京大学人民医院通过检测WHO国际标准品判定自身dPCR及RQ-PCR的CF有效性,并用Bland-Altman一致性分析判断各实验室CF有效性。
  • 参加dPCR比对的实验室有14家,参加RQ-PCR比对的实验室有13家。

主要发现

  • 参加dPCR比对的14家实验室中13家所有比对样本的BCR::ABL1均能检出。
  • 参加RQ-PCR比对的13家实验室中5家CF合格,其余8家重新计算的CF均合格。
  • dPCR比对中11家采用同一商品化试剂盒,10家合格;1家采用自配试剂并利用国家临床检验中心标准品获得CF亦合格;无CF的2家重新计算的CF均合格。
  • 同时进行dPCR和RQ-PCR比对的样本结果显示,各家采用各自合格CF得出的BCR::ABL1(IS)结果差异均无统计学意义(均P≥0.1)。
  • RQ-PCR原有CF不合格的6家实验室中,2家的dPCR检测结果与由原CF得出的BCR::ABL1(IS)结果之间差异有统计学意义(均P<0.05),3家趋于差异有统计学意义(0.05<P<0.1)。

关键数值与推荐

  • CF有效性通过Bland-Altman一致性分析判断,若无合格CF则重新计算并评估有效性。
  • 采用各自合格CF时,各实验室dPCR与RQ-PCR的BCR::ABL1(IS)结果差异均无统计学意义(均P≥0.1)。
  • RQ-PCR原CF不合格的6家实验室中,2家dPCR与原CF的RQ-PCR结果差异有统计学意义(均P<0.05),3家趋于差异有统计学意义(0.05<P<0.1)。

临床怎么用

  • dPCR可作为检测BCR::ABL1(IS)的高敏感性、高准确性方法,与RQ-PCR结果高度一致。
  • 实验室应确保转换系数(CF)合格,CF不合格可能导致BCR::ABL1(IS)结果与dPCR不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the capability of digital PCR (dPCR) in detecting the internationally standardized BCR::ABL1 (P210) mRNA (BCR::ABL1(IS)) of patients with chronic myeloid leukemia through inter-laboratory sample distribution and comparison. Methods: This was a multi-center compatative trial study. A total of 37 samples with different BCR::ABL1(IS) levels were uniformly prepared from patient bone marrow or peripheral blood to be discarded for comparison. Among them, 22 samples were used for real-time reverse transcription quantitative PCR (RQ-PCR) detection to revalidate the conversion factor (CF), whereas another 15 samples, along with 6 samples used in RQ-PCR, were used for dPCR comparison. Peking University People's Hospital determined the validity of its own dPCR and RQ-PCR CFs by detecting World Health Organization international standards. Bland-Altman analysis was conducted to validate the CFs of participating laboratories. If no validated CF was available, the new CF was calculated using the current comparison samples, and its validity was assessed. Results: Among the 14 laboratories participating in the dPCR comparison, 13 detected BCR::ABL1 in all samples. Among the 13 laboratories participating in the RQ-PCR comparison, 5 had validated CFs, whereas the other 8 had validated CFs after recalculating. In the dPCR comparison, 11 laboratories used the same commercial kit, and 10 of them were qualified. Further, 1 laboratory used a laboratory-developed testing reagent and obtained a CF using the standard sample from the National Clinical Laboratory Center, which was also qualified, whereas the 2 laboratories with no CFs both had qualified CFs after calculating. Comparison of results from samples simultaneously performing dPCR and RQ-PCR demonstrated that the BCR::ABL1(IS) results derived from their respective qualified CFs showed no significant difference for each laboratory (all P≥0.1). However, among the 6 laboratories with unqualified original CFs in RQ-PCR, 2 showed significant differences between dPCR results and RQ-PCR results derived from the original CFs (P<0.05), and 3 demonstrated tendencies toward significant differences (P>0.05 to <0.1) . Conclusion: dPCR detection of BCR::ABL1(IS) shows high sensitivity and accuracy and has high consistency with RQ-PCR results. 目的: 通过室间样本派发比对评估数字PCR(dPCR)检测慢性髓细胞性白血病患者国际标准化BCR::ABL1(P210)mRNA(BCR::ABL1(IS))的能力。 方法: 本研究为多中心比对实验研究。采用待废弃的临床样本统一制备共37种不同BCR::ABL1(IS)水平的比对样本,其中22种用于实时定量PCR(RQ-PCR)检测以进行转换系数(CF)的再验证,其余15种加上用于RQ-PCR的6种用于dPCR比对。北京大学人民医院通过检测WHO国际标准品判定自身dPCR及RQ-PCR的CF的有效性。通过Bland-Altman一致性分析判断各实验室CF的有效性,若无合格CF,则重新计算并评估有效性。 结果: 参加dPCR比对的14家实验室中13家所有比对样本的BCR::ABL1均能检出。参加RQ-PCR比对的13家实验室中5家CF合格,其余8家重新计算的CF均合格。dPCR比对中,11家采用同一商品化试剂盒,10家合格;1家采用自配试剂并利用国家临床检验中心标准品获得CF亦合格;无CF的2家重新计算的CF均合格。同时进行dPCR和RQ-PCR比对的样本结果比较显示,各家采用各自合格CF得出的BCR::ABL1(IS)结果差异均无统计学意义(均P≥0.1);但RQ-PCR原有CF不合格的6家实验室中,2家的dPCR检测结果与由原CF得出的BCR::ABL1(IS)结果之间差异有统计学意义(均P<0.05),3家趋于差异有统计学意义(0.05<P<0.1)。 结论: dPCR检测BCR::ABL1(IS)具有高敏感性、高准确性以及与RQ-PCR结果的高度一致性。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Qin YZ, Ma DX, Yao Y, et al. [Inter-laboratory comparison of international standardized BCR::ABL1 (P210) mRNA of chronic myeloid leukemia patients by digital PCR]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42706170. doi:10.3760/cma.j.cn121090-20260123-00054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。